Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22904884 | 1.00 | HRH3 (0.41) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL20963077 | 1.00 | HRH3 (0.41) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL23325027 | 0.88 | HRH3 (0.33) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL18772696 | 0.84 | HRH3 (0.35) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL23104057 | 0.83 | HRH3 (0.39) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL24120049 | 0.83 | CHRM2 (0.39) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL23108965 | 0.83 | HRH3 (0.39) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL16376631 | 0.83 | CHRM2 (0.39) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL23114668 | 0.83 | HRH3 (0.39) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL23104055 | 0.83 | HRH3 (0.39) | HRH3CHRM2HTR1ADRD3HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393919-A1 | LSD1 MODULATORS | Exscientia Al Limited (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7915274-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7871999-B2 | Substituted thiazoles and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2011-01-18 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | OZAKI FUMIHIRO | 2007-12-20 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | HRH3 495/4885CHRM2 243/4885HTR1A 201/4885 |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | HRH3 3345/4885CHRM2 4321/4885HTR1A 1865/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | HRH3 3387/4885CHRM2 4725/4885HTR1A 4702/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | HRH3 1829/4885CHRM2 4059/4885HTR1A 1562/4885 |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | HRH3 4680/4885CHRM2 4885/4885HTR1A 4809/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | HRH3 3548/4885CHRM2 4632/4885HTR1A 3521/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | HRH3 1707/4885CHRM2 1129/4885HTR1A 1530/4885 |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | TPMT, SLC5A2, DPP4 | HRH3 2654/4885CHRM2 3573/4885HTR1A 1632/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885CHRM2 4681/4885HTR1A 3837/4885 |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, ACHE | HRH3 2541/4885CHRM2 514/4885HTR1A 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.